Details of Disease

General Information of Disease (ID: DISQZQ70)

Disease Name Nephritis
Synonyms kidney inflammation; inflammation of kidney
Disease Class GB40: Nephritic syndrome
Definition Inflammation of renal tissue.
Disease Hierarchy
DISWD40R: Disease
DISXWP4P: Nephropathy
DIS184KT: Skin inflammation
DISQZQ70: Nephritis
ICD Code
ICD-11
ICD-11: GB40
Expand ICD-11
'GB40
Expand ICD-10
'N00; 'N00.0; 'N00.1; 'N00.3; 'N00.4; 'N00.5; 'N00.6; 'N00.7; 'N00.9; 'N01; 'N01.0; 'N01.1; 'N01.3; 'N01.4; 'N01.5; 'N01.6; 'N01.7; 'N01.9; 'N03; 'N03.0; 'N03.1; 'N03.3; 'N03.4; 'N03.5; 'N03.6; 'N03.7; 'N03.9; 'N05; 'N05.0; 'N05.5; 'N05.9
Disease Identifiers
MONDO ID
MONDO_0001166
MESH ID
D009393
UMLS CUI
C0027697
MedGen ID
14328
HPO ID
HP:0000123
SNOMED CT ID
52845002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Bindarit DMS2GA1 Phase 3 Small molecular drug [1]
TEI-5178 DMHJQYS Phase 1 Small molecular drug [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Rolafagrel DM8Q7XV Discontinued in Phase 2 Small molecular drug [3]
TJ-8117 DM8YRYD Discontinued in Phase 2 NA [4]
Acteoside DM0YHKB Terminated Small molecular drug [5]
TO-195 DMIBGZK Terminated NA [6]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AG-NPN803 DMPY9XA Investigative NA [7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 36 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
FAS TT7LTUJ Limited Biomarker [8]
FCGR2B TT5RWKQ Limited Biomarker [9]
LEPR TT0HD6V Limited Biomarker [10]
PLAU TTGY7WI Limited Therapeutic [11]
ALB TTFNGC9 Disputed Biomarker [12]
HSPE1 TTWYMFE moderate Biomarker [13]
UCHL1 TTX9IFP moderate Biomarker [14]
AGTR1 TT8DBY3 Strong Biomarker [15]
CASP8 TT6SZNG Strong Therapeutic [16]
CCL3 TT8I4WB Strong Biomarker [17]
CCR5 TTJIH8Q Strong Biomarker [18]
CXCR2 TT30C9G Strong Genetic Variation [19]
CYP2J2 TTNE1C7 Strong Biomarker [20]
DNASE1 TTYWGOJ Strong Genetic Variation [21]
EDN1 TTJR60Z Strong Therapeutic [22]
FCAR TTGUJAO Strong Altered Expression [23]
FCGR2A TTXT21W Strong Biomarker [24]
GAS6 TT69QD2 Strong Altered Expression [25]
HLA-B TTGS10J Strong Biomarker [26]
ICAM1 TTA1L39 Strong Altered Expression [27]
IL4 TTLGTKB Strong Altered Expression [28]
ITGA4 TTJMF9P Strong Therapeutic [29]
ITGAL TT48WR6 Strong Therapeutic [30]
ITGB2 TTIJWR7 Strong Therapeutic [30]
LGALS1 TTO3NYT Strong Therapeutic [31]
LTA TTP73TM Strong Genetic Variation [32]
MTNR1A TT0WAIE Strong Altered Expression [33]
NLRP1 TTQX29T Strong Altered Expression [34]
PTGDR2 TTQDMX5 Strong Biomarker [35]
PTGER2 TT1ZAVI Strong Biomarker [36]
PTK2 TTON5IT Strong Therapeutic [37]
PTK2B TTTEFBV Strong Therapeutic [37]
SLC15A4 TTG2XRE Strong Genetic Variation [38]
SMAD6 TTON5JB Strong Biomarker [39]
SMAD7 TT0J32Z Strong Biomarker [39]
ST8SIA4 TTDP8YM Strong Genetic Variation [40]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC7A9 DTP7AEQ Strong Genetic Variation [41]
------------------------------------------------------------------------------------
This Disease Is Related to 46 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
C1QA OT6XKVVA Limited Biomarker [42]
CAMK4 OT47RDGV Limited Biomarker [43]
COL4A3 OT6SB8X5 Limited Genetic Variation [44]
FCN2 OTTHJBKZ Limited Biomarker [45]
IKBKG OTNWJWSD Disputed Biomarker [46]
AIMP1 OTTA5C3U moderate Biomarker [47]
IGBP1 OTTHH4YE moderate Altered Expression [48]
OTUB1 OT8WWM9O moderate Altered Expression [49]
TRAP1 OTNG0L8J moderate Altered Expression [50]
ACKR2 OTWYY14H Strong Altered Expression [51]
ALG1 OTVXPA9E Strong Altered Expression [33]
CCND2 OTDULQF9 Strong Biomarker [52]
CD1C OT4XINUJ Strong Biomarker [53]
CLDN2 OTRF3D6Y Strong Biomarker [54]
COL4A5 OTHG60RE Strong Genetic Variation [55]
DDX39A OT0Z6E1K Strong Genetic Variation [41]
DDX39B OTEVCFVU Strong Genetic Variation [41]
FLI1 OT0EV3LX Strong Altered Expression [56]
HVCN1 OT4ALYU4 Strong Biomarker [57]
IL10RA OTOX3D1D Strong Biomarker [58]
IL17RD OTKD9XST Strong Altered Expression [59]
IL18BP OTW0LRYZ Strong Biomarker [60]
LST1 OTUVG424 Strong Genetic Variation [41]
MT1B OTUA4FFH Strong Altered Expression [33]
MT1F OTZVUYG1 Strong Altered Expression [33]
MT1G OTAV1OCR Strong Altered Expression [33]
MT1H OT0MVBM6 Strong Altered Expression [33]
MT1M OTVT8PLU Strong Altered Expression [33]
MT1X OT9AKFVS Strong Altered Expression [33]
MYH9 OT94Z706 Strong Genetic Variation [61]
NEIL3 OTBCI2NS Strong Biomarker [62]
NLRP6 OTEREN4W Strong Biomarker [63]
NPHS2 OTLCNUII Strong Biomarker [64]
PAX2 OTKP1N8F Strong Genetic Variation [65]
PTPRO OTFLKWOY Strong Biomarker [66]
RASGRP3 OTEMEV3P Strong Genetic Variation [38]
SEMA5A OTUOIOJV Strong Altered Expression [67]
SERPINB7 OTZ95LR2 Strong Biomarker [68]
SNRPA OT02TSQT Strong Biomarker [69]
SNRPD1 OTWKZV4E Strong Biomarker [70]
SPAG11A OTNQ9UB0 Strong Biomarker [36]
STAT4 OTAK3VFR Strong Biomarker [71]
THEMIS2 OTI1OBLN Strong Biomarker [72]
THY1 OTVONVTB Strong Biomarker [73]
TIMP4 OT8A68SW Strong Altered Expression [74]
LGALS9 OT7MF91K Definitive Biomarker [75]
------------------------------------------------------------------------------------
⏷ Show the Full List of 46 DOT(s)

References

1 Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69.
2 Antinephritic effects of PGE1 and thiaprostaglandin E1, TEI-5178 and TEI-6122, on crescentic-type anti-GBM nephritis in rats. Jpn J Pharmacol. 1989 Dec;51(4):521-30.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001438)
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010241)
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003095)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003122)
7 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
8 Therapeutic targeting of BET protein BRD4 delays murine lupus.Int Immunopharmacol. 2015 Dec;29(2):314-319. doi: 10.1016/j.intimp.2015.10.036. Epub 2015 Nov 14.
9 Lupus nephritis progression in FcRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease.PLoS One. 2017 Nov 30;12(11):e0188863. doi: 10.1371/journal.pone.0188863. eCollection 2017.
10 Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus.World J Diabetes. 2018 Jun 15;9(6):80-91. doi: 10.4239/wjd.v9.i6.80.
11 Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schnlein nephritis.Pediatrics. 2003 Apr;111(4 Pt 1):785-9. doi: 10.1542/peds.111.4.785.
12 Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome.Lupus. 2019 Jan;28(1):123-128. doi: 10.1177/0961203318811603. Epub 2018 Nov 15.
13 Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice.Nephrol Dial Transplant. 2012 Apr;27(4):1358-67. doi: 10.1093/ndt/gfr544. Epub 2011 Oct 10.
14 Wnt/-Catenin Signaling Mediated-UCH-L1 Expression in Podocytes of Diabetic Nephropathy.Int J Mol Sci. 2016 Aug 25;17(9):1404. doi: 10.3390/ijms17091404.
15 Renoprotective mechanisms of angiotensin II antagonism in experimental chronic renal failure.Kidney Blood Press Res. 2002;25(2):71-9. doi: 10.1159/000063511.
16 Sublytic C5b-9 Induces Glomerular Mesangial Cell Apoptosis through the Cascade Pathway of MEKK2-p38 MAPK-IRF-1-TRADD-Caspase 8 in Rat Thy-1 Nephritis.J Immunol. 2017 Feb 1;198(3):1104-1118. doi: 10.4049/jimmunol.1600403. Epub 2016 Dec 30.
17 The effects of dietary fish oil on inflammation, fibrosis and oxidative stress associated with obstructive renal injury in rats.Mol Nutr Food Res. 2011 Mar;55(3):400-10. doi: 10.1002/mnfr.201000195. Epub 2010 Oct 28.
18 CCR5 deficiency increased susceptibility to lipopolysaccharide-induced acute renal injury.Arch Toxicol. 2016 May;90(5):1151-62. doi: 10.1007/s00204-015-1530-9. Epub 2015 Jun 9.
19 CXCR1/CXCR2 antagonist G31P inhibits nephritis in a mouse model of uric acid nephropathy.Biomed Pharmacother. 2018 Nov;107:1142-1150. doi: 10.1016/j.biopha.2018.07.077. Epub 2018 Aug 28.
20 Macrophage epoxygenase determines a profibrotic transcriptome signature.J Immunol. 2015 May 15;194(10):4705-4716. doi: 10.4049/jimmunol.1402979. Epub 2015 Apr 3.
21 Q222R polymorphism in DNAse I gene is a risk factor for nephritis in South Indian SLE patients.Lupus. 2013 Sep;22(10):996-1000. doi: 10.1177/0961203313498801.
22 Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis.J Am Soc Nephrol. 1997 May;8(5):756-68. doi: 10.1681/ASN.V85756.
23 Murine Models of Human IgA Nephropathy.Semin Nephrol. 2018 Sep;38(5):513-520. doi: 10.1016/j.semnephrol.2018.05.021.
24 Neutrophil FcRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.J Clin Invest. 2017 Oct 2;127(10):3810-3826. doi: 10.1172/JCI94039. Epub 2017 Sep 11.
25 Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus.Clin Rheumatol. 2020 Feb;39(2):509-514. doi: 10.1007/s10067-019-04799-5. Epub 2019 Oct 26.
26 Toxicity due to remission inducing drugs in rheumatoid arthritis. Association with HLA-B35 and Cw4 antigens.J Rheumatol. 1986 Feb;13(1):65-8.
27 Tumor necrosis factor-alpha up-regulates the expression of CCL2 and adhesion molecules of human proximal tubular epithelial cells through MAPK signaling pathways.Immunobiology. 2008;213(7):533-44. doi: 10.1016/j.imbio.2008.01.003. Epub 2008 Feb 20.
28 Co-regulated expression of glomerular 12/15-lipoxygenase and interleukin-4 mRNAs in rat nephrotoxic nephritis.Kidney Int. 1994 Aug;46(2):341-9. doi: 10.1038/ki.1994.280.
29 Differential effects of antibodies to vascular cell adhesion molecule-1 and distinct epitopes of the alpha4 integrin in HgCl2-induced nephritis in Brown Norway rats.J Am Soc Nephrol. 1998 Oct;9(10):1881-91. doi: 10.1681/ASN.V9101881.
30 The critical role of intercellular adhesion molecule-1 in Masugi nephritis in rats.Nephron. 1996;73(2):264-72. doi: 10.1159/000189050.
31 Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.Kidney Int. 2000 Nov;58(5):1941-52. doi: 10.1111/j.1523-1755.2000.00366.x.
32 TNF promoter -308 G>A and LTA 252 A>G polymorphisms in Portuguese patients with systemic lupus erythematosus.Rheumatol Int. 2012 Aug;32(8):2239-44. doi: 10.1007/s00296-011-1950-7. Epub 2011 May 5.
33 The renal metallothionein expression profile is altered in human lupus nephritis.Arthritis Res Ther. 2008;10(4):R76. doi: 10.1186/ar2450. Epub 2008 Jul 6.
34 N-Acetylcysteine Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting the C5a Receptor.Biomed Res Int. 2019 Apr 14;2019:4805853. doi: 10.1155/2019/4805853. eCollection 2019.
35 Innate lymphoid cells are increased in systemic lupus erythematosus.Clin Exp Rheumatol. 2019 Jul-Aug;37(4):676-679. Epub 2019 Feb 15.
36 Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis.Inflamm Res. 2000 Jul;49(7):345-54. doi: 10.1007/PL00000215.
37 [Effects of prednisone on renal FAK and Pyk2 expressions in rats with adriamycin- induced nephritis].Nan Fang Yi Ke Da Xue Xue Bao. 2014 Jul;34(8):1149-53.
38 TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population.Lupus. 2010 Sep;19(10):1181-6. doi: 10.1177/0961203310367918. Epub 2010 Jun 1.
39 Localization of Smad6 and Smad7 in the rat kidney and their regulated expression in the anti-Thy-1 nephritis.Mol Cell Biol Res Commun. 2000 Aug;4(2):98-105. doi: 10.1006/mcbr.2000.0258.
40 Identification of mutations in the COL4A5 collagen gene in Alport syndrome.Science. 1990 Jun 8;248(4960):1224-7. doi: 10.1126/science.2349482.
41 Haplotype-specific gene expression profiles in a telomeric major histocompatibility complex gene cluster and susceptibility to autoimmune diseases.Genes Immun. 2006 Dec;7(8):625-31. doi: 10.1038/sj.gene.6364339. Epub 2006 Sep 14.
42 Evaluation of C1q genomic region in minority racial groups of lupus.Genes Immun. 2009 Jul;10(5):517-24. doi: 10.1038/gene.2009.33. Epub 2009 May 14.
43 Calcium/Calmodulin Kinase IV Controls the Function of Both T Cells and Kidney Resident Cells.Front Immunol. 2018 Oct 1;9:2113. doi: 10.3389/fimmu.2018.02113. eCollection 2018.
44 Autosomal recessive Alport syndrome: mutation in the COL4A3 gene in a woman with Alport syndrome and posttransplant antiglomerular basement membrane nephritis.J Am Soc Nephrol. 1995 Mar;5(9):1714-7. doi: 10.1681/ASN.V591714.
45 Autoantibodies Targeting Ficolin-2 in Systemic Lupus Erythematosus Patients With Active Nephritis.Arthritis Care Res (Hoboken). 2018 Aug;70(8):1263-1268. doi: 10.1002/acr.23449. Epub 2018 Jun 21.
46 T-lymphocyte-specific knockout of IKK-2 or NEMO induces T(h)17 cells in an experimental nephrotoxic nephritis mouse model.FASEB J. 2019 Feb;33(2):2359-2371. doi: 10.1096/fj.201800485RR. Epub 2018 Oct 4.
47 Atializumab, a humanized anti-aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) antibody significantly improves nephritis in (NZB/NZW) F1 mice.Biomaterials. 2019 Nov;220:119408. doi: 10.1016/j.biomaterials.2019.119408. Epub 2019 Aug 2.
48 Immunoglobulin Binding Protein 1 as a Potential Urine Biomarker in Patients with Lupus Nephritis.Int J Mol Sci. 2019 May 27;20(10):2606. doi: 10.3390/ijms20102606.
49 OTUB1 overexpression in mesangial cells is a novel regulator in the pathogenesis of glomerulonephritis through the decrease of DCN level.PLoS One. 2012;7(1):e29654. doi: 10.1371/journal.pone.0029654. Epub 2012 Jan 18.
50 Impact of the tumor necrosis factor receptor-associated protein 1 (Trap1) on renal DNaseI shutdown and on progression of murine and human lupus nephritis.Am J Pathol. 2013 Mar;182(3):688-700. doi: 10.1016/j.ajpath.2012.11.013. Epub 2012 Dec 27.
51 The atypical chemokine receptor 2 limits renal inflammation and fibrosis in murine progressive immune complex glomerulonephritis.Kidney Int. 2018 Apr;93(4):826-841. doi: 10.1016/j.kint.2017.11.013. Epub 2018 Feb 1.
52 Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.Clin Exp Immunol. 2005 Feb;139(2):225-35. doi: 10.1111/j.1365-2249.2004.02684.x.
53 Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis.Mol Immunol. 2010 Jul;47(11-12):2129-37. doi: 10.1016/j.molimm.2010.02.006. Epub 2010 Apr 24.
54 Ectopic expression of CLDN2 in podocytes is associated with childhood onset nephrotic syndrome.Pediatr Res. 2019 Oct;86(4):485-491. doi: 10.1038/s41390-019-0423-7. Epub 2019 May 13.
55 Common ancestry of three Ashkenazi-American families with Alport syndrome and COL4A5 R1677Q.Hum Genet. 1997 May;99(5):681-4. doi: 10.1007/s004390050429.
56 FLI1 Levels Impact CXCR3 Expression and Renal Infiltration of T Cells and Renal Glycosphingolipid Metabolism in the MRL/lpr Lupus Mouse Strain.J Immunol. 2015 Dec 15;195(12):5551-60. doi: 10.4049/jimmunol.1500961. Epub 2015 Nov 4.
57 Autoimmune disorder phenotypes in Hvcn1-deficient mice.Biochem J. 2013 Mar 1;450(2):295-301. doi: 10.1042/BJ20121188.
58 IL-10 Receptor Signaling Empowers Regulatory T Cells to Control Th17 Responses and Protect from GN.J Am Soc Nephrol. 2018 Jul;29(7):1825-1837. doi: 10.1681/ASN.2017091044. Epub 2018 Jun 4.
59 Tumor necrosis factor receptor 2 (TNFR2)interleukin-17 receptor D (IL-17RD) heteromerization reveals a novel mechanism for NF-B activation.J Biol Chem. 2015 Jan 9;290(2):861-71. doi: 10.1074/jbc.M114.586560. Epub 2014 Nov 5.
60 IL-1 family cytokines and soluble receptors in systemic lupus erythematosus.Arthritis Res Ther. 2018 Feb 8;20(1):27. doi: 10.1186/s13075-018-1525-z.
61 Cellular force assay detects altered contractility caused by a nephritis-associated mutation in nonmuscle myosin IIA.Dev Growth Differ. 2017 Jun;59(5):423-433. doi: 10.1111/dgd.12379. Epub 2017 Jul 17.
62 Genetic cause of immune dysregulation - one gene or two?.J Clin Invest. 2016 Nov 1;126(11):4065-4067. doi: 10.1172/JCI90831. Epub 2016 Oct 17.
63 Loss of NLRP6 expression increases the severity of acute kidney injury.Nephrol Dial Transplant. 2020 Apr 1;35(4):587-598. doi: 10.1093/ndt/gfz169.
64 Lack of association between NPHS2 gene polymorphisms and Henoch-Schnlein purpura nephritis.Arch Dermatol Res. 2007 Jun;299(3):151-5. doi: 10.1007/s00403-007-0752-y. Epub 2007 Mar 29.
65 Association of the paired box 2 gene polymorphism with the susceptibility and pathogenesis of HenochSchnlein purpura in children.Mol Med Rep. 2015 Mar;11(3):1997-2003. doi: 10.3892/mmr.2014.2908. Epub 2014 Nov 10.
66 Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man.Lab Invest. 1996 Mar;74(3):571-84.
67 Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.Clin Exp Immunol. 2017 May;188(2):234-242. doi: 10.1111/cei.12924. Epub 2017 Feb 17.
68 Cloning of rodent megsin revealed its up-regulation in mesangioproliferative nephritis.Kidney Int. 2001 Aug;60(2):641-52. doi: 10.1046/j.1523-1755.2001.060002641.x.
69 Structural availability influences the capacity of autoantigenic epitopes to induce a widespread lupus-like autoimmune response.Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3551-6. doi: 10.1073/pnas.0306267101. Epub 2004 Feb 26.
70 Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases.J Autoimmun. 2001 Dec;17(4):347-54. doi: 10.1006/jaut.2001.0545.
71 Systemic lupus erythematosus: still a challenge for physicians.J Intern Med. 2017 Jan;281(1):52-64. doi: 10.1111/joim.12529. Epub 2016 Jun 16.
72 Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice.J Immunol. 2017 Apr 1;198(7):2589-2601. doi: 10.4049/jimmunol.1601565. Epub 2017 Feb 20.
73 The role of transcriptional factor D-site-binding protein in circadian CCL2 gene expression in anti-Thy1 nephritis.Cell Mol Immunol. 2019 Sep;16(9):735-745. doi: 10.1038/s41423-018-0020-4. Epub 2018 Mar 22.
74 The gene expression profile of matrix metalloproteinases and their inhibitors in children with Henoch-Schnlein purpura.Br J Dermatol. 2011 Jun;164(6):1348-55. doi: 10.1111/j.1365-2133.2011.10295.x.
75 Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane-Induced Lupus Model.Arthritis Rheumatol. 2018 Jul;70(7):1089-1101. doi: 10.1002/art.40467. Epub 2018 May 24.